Applicant : Tuo Jin
U.S. Serial No.: 10/606,344
Filed : June 25, 2003
Page : 2

In the claims

1. (Previously presented) A composition in the form of a free flowing, compressible powder that facilitates dissolution and water dispersion of poorly soluble or insoluble compounds.

2. (Previously presented) The composition of claim 1 comprising a solid lipid or a solid lipid mixture that dissolves water-insoluble or poorly soluble compounds and is able to be absorbed by a porous powder or a mixture of porous powders at melt state, and forms solutions, micelles, microemulsion or emulsion with the compounds in an aqueous medium.

3. (Previously presented) The composition of claim 1 comprising a porous powder or a mixture of porous powders that absorb melted lipids.

4. (Previously presented) The composition of claim 1 comprising, at least, a compound that dissolves in the lipids and forms solutions, micelles, microemulsion or emulsion with the lipids in an aqueous medium.

5. (Previously presented) The composition of claim 1 wherein said the composition facilitates formation of solutions, micelles, microemulsions or emulsions of poorly soluble or water-insoluble compounds and the lipids after administration with no need of pre-emulsification of the compounds during formulation.

6. (Previously presented) The composition of claim 2 wherein the lipids are amphiphilic compounds.

7. (Previously presented) The composition of claim 6, wherein the lipid is Gelucire, vitamin E TPGS, Bay 10, fatty acids, phospholipids, or non-phospholipids.

8. (Previously presented) The composition of claim 3, wherein the porous powders are nontoxic solids possessing sufficient specific surface area and pore structure .

9. (Previously presented) The composition of claim 8, wherein the surface area is bigger than 100 m^2/g.

10. (Previously presented) The composition of claim 8, wherein the pore structure has a diameter less than 50 nm).

11. (Previously presented) The composition of claim 10, wherein the pore structure is alumina, silica or cellulose derivatives

12. (Previously presented) The composition of claim 4, wherein the compound is cyclosporine, triamterene, acyclovir, doxorubicin, labetalol, doxepin, methyldopa or pentoxifill.

13. (Currently amended) A pharmaceutical composition comprising the composition of claim 1~~-12~~ and a pharmaceutically acceptable carrier.

14. (Currently amended) A method for producing the composition of claim [[1]] 2, comprising steps of:

a) Melting the said solid lipid or lipid mixture by heating;

b) Dissolving the said compound in melted lipid or lipid mixtures;

c) Impregnating the said porous powders with the drug-lipid melt; and

d) Cooling the porous powder impregnated with the drug-lipid melt to room temperature to solidify the drug-lipid melt.

~~d) Dissolving the said compound in melted lipid or lipid mixtures~~

~~e) Impregnating the said porous powders with the drug-lipid melt; and~~

~~f) Solidifying the drug-lipid melt absorbed in the porous powders by cooling, thereby producing the composition.~~

15. (Previously presented) The method of claim 14, further comprising granulation, capsule filling, tableting, coating and paste making of the produced composition.

16. (Previously presented) The composition produced by the method of claim 14.

17. (Previously presented) A pharmaceutical composition which comprises the composition of claim 16.

18. (Previously presented) The composition of claim 16, formulated in powders, capsules, granules, coated granules, tablets or coated tablets.

19. (Previously presented) The formulated composition of claim 18, comprising the excipients selected from the group containing binders, diluents, disintegrants, coating material, and lubricants.